Cosmos Health(COSM.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Cosmos Health
COSM.US
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).
233.03 B
COSM.USMarket value -Rank by Market Cap -/-

Financial Score

15/01/2026 Update
C
Health Care DistributorsIndustry
Industry Ranking10/14
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-63.82%E
    • Profit Margin-31.01%E
    • Gross Margin15.21%D
  • Growth ScoreC
    • Revenue YoY6.69%C
    • Net Profit YoY45.16%B
    • Total Assets YoY7.71%B
    • Net Assets YoY-33.86%E
  • Cash ScoreC
    • Cash Flow Margin-322.47%D
    • OCF YoY6.69%C
  • Operating ScoreB
    • Turnover0.89B
  • Debt ScoreD
    • Gearing Ratio66.71%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cosmos Health CEO Grigorios Siokas Reports Acquisition of Common Shares

    Grigorios Siokas, CEO of Cosmos Health Inc., announced the acquisition of common shares as a beneficial owner. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published via EDGAR by Cosmos Health Inc. on January 15, 2026.

    Reuters·
    US
    COSM
    +26.56%
    Reuters·
    US
    COSM
    +26.56%

    Cosmos Health initiated analyst coverage, valued at $4.50 per share by Zacks Small-Cap Research on Jan 13, 2026.

    On January 14, 2026, Cosmos Health Inc. revealed that Zacks Small-Cap Research has begun covering the company, valuing it at $4.50 per share. Cosmos Health, listed on NASDAQ as COSM, is a worldwide healthcare conglomerate. This assessment was made in a report by analyst Brad Sorensen on January 13, 2026.

    Unusual Whales·
    US
    COSM
    +26.56%
    Unusual Whales·
    US
    COSM
    +26.56%

    Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research | COSM Stock News

    Cosmos Health Inc. (NASDAQ:COSM) announced that Zacks Small-Cap Research has initiated coverage with a valuation of $4.50 per share. The report highlights the company's diversified revenue, vertical integration, and expansion into the U.S. market as key factors. Zacks projects revenue growth from $64.4 million in 2025 to $98.6 million in 2026, driven by higher-margin products. The report also notes advancements in R&D, including AI-driven drug repurposing, and a digital asset strategy. CEO Greg Siokas emphasized the company's transformation and potential for long-term value creation for shareholders.

    StockTitan·
    US
    COSM
    +26.56%
    StockTitan·
    US
    COSM
    +26.56%

    Symbotic Inc. Director Todd Krasnow Reports Sale of Common Shares

    Todd Krasnow, Director at Symbotic Inc., has reported the sale of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Symbotic Inc. is responsible for the original content published via EDGAR on January 08, 2026.

    Reuters·
    US
    SYM
    -1.13%
    Reuters·
    US
    SYM
    -1.13%

    Cosmos Health Inc. CEO Grigorios Siokas Acquires Common Shares

    Grigorios Siokas, CEO of Cosmos Health Inc., has acquired common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published via EDGAR by Cosmos Health Inc. on January 07, 2026.

    Reuters·
    US
    COSM
    +26.56%
    Reuters·
    US
    COSM
    +26.56%
    © 2026 Longbridge｜Disclaimer